Lorenzo Gentiloni Silveri

Title: Partner
Office: Rome
Languages: English, Italian

Lorenzo has a notable expertise in life sciences & healthcare, providing assistance since several years to leading operators in this area (including hospitals and other healthcare facilities, diagnostic centers, pharmaceutical companies, manufacturers and distributors of medical devices, universities, Scientific Institutes of Hospitalisation and Care (IRCCS) and foundations).

He mainly deals with M&A transactions and all issues of corporate, civil, commercial and compliance law related to hospital, pharmaceutical, medical devices, scientific research, artificial intelligence, digital health, veterinary and animal care areas, as well as authorisation and accreditation system of healthcare facilities with the National Health Service.

In recent years Lorenzo has been involved, among others, in major M&A transactions between players in the healthcare and insurance sectors that have enabled the introduction of new business models in the Italian market, as well as the first projects applying artificial intelligence to the healthcare sector for the development of revolutionary solutions.

Lorenzo also advises and assists national and international clients in relation to M&A transactions and corporate and commercial law matters in other sectors, and he has gained significant experience in civil and commercial litigation and in restructuring.

Lorenzo lectures at Università Vita-Salute San Raffaele (Milan).

The Legal 500 mentions Lorenzo in the Healthcare and Life Sciences section as follows: “Lorenzo Gentiloni Silveri is an outstanding lawyer with a wide range of abilities. His work is always done very quickly but is always precise” (2023), “He is outstanding for competence, timeliness and dedication, as well as for flexibility in adapting the approach to the specific needs of the client by providing advice that is strategically valuable”, “I work closely with Lorenzo Gentiloni and am very satisfied with the work produced by him and his team” (2022).